Corticosteroid Tapering After Remission: How Much is Enough? Authors: Sumedh Jayanti, Bhadran Bose Published: 2026 See Clinical Research on Article 107004 See Clinical Research on Article 107004 Steroid-sensitive podocytopathies encompass a wide spectrum of disease, from minimal change disease (MCD) to primary focal segmental glomerulosclerosis (FSGS). These conditions share clinical steroid responsiveness but remain heterogeneous in pathological features, relapse risk, and long-term outcomes. In adult MCD, approximately 50% to 75% of patients experience at least 1 relapse, and up to one-third develop frequently relapsing or steroid-dependent disease.1 FSGS relapse rates vary, in part because retrospective studies often group primary FSGS with genetic and secondary causes that tend not to respond to immunosuppression. A large retrospective study of primary FSGS alone reported a relapse rate of 56%.2 Current Kidney Disease: Improving Global Outcomes guidelines recommend managing relapsing MCD and FSGS with a prolonged course of corticosteroids (up to 4 months).1 However, these recommendations provide limited evidence on how corticosteroids should be withdrawn once remission has been achieved. In adult MCD, tapers have traditionally extended over several months, largely because of concern that earlier withdrawal could increase relapse.3 Previous support for abbreviated tapering has come primarily from small observational studies rather than adequately controlled trials.4,5 Appropriate steroid withdrawal therefore matters—relapse is common, yet prolonged corticosteroid exposure carries substantial infectious and metabolic toxicity. The study by Prabahar et al.6 therefore addresses a distinct and important question—once steroid sensitivity has been demonstrated and remission achieved, does shortening the corticosteroid taper to 2 months provide meaningful protection against relapse relative to a longer course? What is the START Trial? The Steroid Tapering Protocol in Adult Nephrotic Syndrome due to Podocytopathy – A Randomized Controlled Trial of 2 Regimens (START) was an open-label study that randomized 94 adults with biopsy-proven, treatment-naive or infrequently relapsing MCD or FSGS at 2 centers in India between May 2021 and May 2023. Participants achieved remission (reduction in proteinuria to less than 0.5 g/day) with prednisolone alone and were then assigned to a 2- or 4-month corticosteroid taper. The primary outcome was relapse-free remission assessed at 12 months after randomization. Secondary outcomes were time to first relapse, relapse-free remission stratified by MCD and FSGS subgroups, cumulative prednisolone dose, and safety profile. The primary analysis was a noninferiority comparison of relapse-free remission at 12 months, with the absolute risk difference assessed using a 1-sided Newcombe–Wilson test at a significance level of 0.025. The remaining outcomes were assessed on an exploratory basis. Overall, 45 patients were assigned to the 4-month group and 49 to the 2-month group. The mean age was 31.9 ± 11.1 years, and 60.6% of participants were male. Patients were nearly equally split between MCD (51.1%) and FSGS (48.9%), and between treatment-naive (55.3%) and infrequently relapsing disease (44.7%). Relapse-free remission occurred in 63.3% of the 2-month group and 57.8% of the 4-month group, an absolute difference of 5.5% (P = 0.001); the lower bound of the 95% confidence interval (-14.3%) remained above the prespecified noninferiority margin of -25%. Postrandomization prednisolone exposure was approximately halved in the 2-month group (median 1750 mg vs. 3430 mg in the 4-month group), whereas adverse events were more common in the 4-month group than in the 2-month group (53.3% vs. 24.5%). Serious adverse events were uncommon; the 2 serious infections requiring hospitalization occurred in the 2-month group. The trial therefore supports a reduction in overall reported toxicity but does not establish that a shorter taper reduces serious infection, hospitalization, or long-term complications. Among the 48 patients with MCD, relapse-free remission numerically favored the 2-month taper (75% vs. 55%); among the 46 patients with FSGS, relapse-free remission was numerically lower with the 2-month taper (47.6% vs. 60%). What Does the START Trial Add? The primary outcome, assessed by noninferiority analysis, showed that the 2-month taper was noninferior to the 4-month taper for relapse-free remission at 12 months. The principal uncertainty concerns whether the -25% noninferiority margin represents a clinically acceptable loss of efficacy.7 The investigators justify this margin on the basis of the expected reduction in steroid exposure and the absence of previous randomized trials in adults. The observed point estimate favored the 2-month taper, but the confidence interval warrants a more cautious interpretation—its lower limit indicates that the results remain compatible with the shorter regimen causing approximately 14 additional relapses per 100 patients by 12 months. Some clinicians and patients may regard this potential reduction in efficacy as an acceptable trade-off for substantially lower steroid exposure; others may not, particularly where relapse has previously been severe or complicated by acute kidney injury, infection, or thrombosis. Several aspects of the trial strengthen its clinical relevance. Treatment allocation was randomized and concealed, the tapering strategies were pragmatic and readily reproducible, and the primary outcome was recurrence of nephrotic syndrome rather than a surrogate change in proteinuria. By the 12-month assessment, both groups had completed corticosteroid treatment, reducing the likelihood that observed differences in remission simply reflected participants remaining on different corticosteroid doses at the time of assessment. The inclusion of nearly equal numbers of patients with MCD and FSGS enhances the study’s pragmatic nature but complicates its interpretation. MCD and primary FSGS can present with nephrotic syndrome and be steroid-responsive, yet FSGS is a histological pattern that encompasses primary podocyte injury, genetic disorders, and maladaptive or secondary podocyte injury. A nephrotic presentation and steroid responsiveness increase the likelihood of primary FSGS but do not independently establish a uniform underlying pathogenesis. Electron microscopy was not mandatory, and systematic genetic testing was not reported, leaving some uncertainty regarding the classification of the FSGS population.8 Both subgroup estimates had wide confidence intervals, and no statistically significant interaction between taper duration and disease subtype was demonstrated; these subgroup findings should therefore not be used to claim that taper duration has different effects in MCD and FSGS. Generalizability is limited by the relatively healthy study population. Participants were young and had already tolerated and responded to high-dose prednisolone. Patients with diabetes, previous steroid intolerance, recent immunosuppressive exposure, persistent kidney dysfunction, or secondary causes of nephrotic syndrome were excluded. The results do not directly apply to steroid-resistant FSGS, frequently relapsing or steroid-dependent disease, older adults with substantial comorbidity, or patients in whom induction therapy must be curtailed because of toxicity. What are the Future Implications? For young adults with biopsy-proven, steroid-sensitive podocytopathy who have achieved remission and resemble participants in the START trial, a 2-month taper is a reasonable option that substantially reduces corticosteroid exposure. The START trial poses an important challenge to the assumption that prolonged corticosteroid tapering is inherently protective. Future trials should aim to recruit sufficient numbers to allow randomization stratified by MCD and FSGS, use a more conservative noninferiority margin, and incorporate systematic clinicopathological and genetic classification. Less corticosteroid may indeed be enough for many adults with steroid-sensitive podocytopathy, and defining precisely which patients can safely receive less remains the next priority. Disclosure The authors declared no competing interests.